SHANDONG XINHUA (00719) announced that the company has recently received the Drug Registration Certificate for Bisoprolol Fumarate Tablets, approved and issued by the National Medical Products Administration. The approval of this product further enriches the company's cardiovascular and cerebrovascular product portfolio, providing additional options for clinical medication.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.